Академический Документы
Профессиональный Документы
Культура Документы
EPF workshop
Jrme Boehm
18 May 2010
Presentation outline
Definitions and concepts
EC messages on HTA cooperation
Patients perspective
Instruments to support the
cooperation
Conclusions
2
HTA definitions
Healthcare technology is defined as prevention
and rehabilitation, vaccines, pharmaceuticals
and devices, medical and surgical procedures,
and the systems within which health is
protected and maintained.
Health technology assessment (HTA) is an
approach to evaluate the relative effect a given
health technology has on a medical condition:
Is the technology effective?
For whom does it work?
What costs are entailed?
How well does it work compared to alternative
technologies?
HTA definitions
Pharmaceuticals:15-20% of overall
health care budgets but 80% of all HTA's
produced. HTA methodologies are rather
well elaborated.
Medical devices: the efficacy depends
not only on the device itself, but on how
it is used. HTA methods are complex
For health interventions: only ad-hoc
HTA methods
4
Patients perspective
The big issues on HTA
Should there be a price for life?
Should it meet overall or conditions
specific interests?
Should patients be involved in the HTA
process?
Patients perspectives
The paradigms:
Sustainability of HCS is at stake: need to meet
challenges of the ageing populations within
given financial resources
Patients have increased expectations on life
expectancy & access to treatment but are also
payers
Patients tend to pledge for their own condition:
there should be no disease specific
discrimination but severity criteria
9
Patients perspectives
SANCO views on patients perspectives
Keep in mind the three objectives:
patient satisfaction, reward for
innovation, cost containment
Promote overall interest: one patients
voice is welcome, as for consumers
Engage in the HTA process: develop
expertise, gather solid evidence on
treatment, QoL to deal with HTA bodies
10
SW presidency compromise
EP supportive in 1st reading,
discussions on going in Council
Agreement on a long term and
sustainable cooperation on HTA
Implementation issues to be
discussed. Several scenarios to be
envisaged
13
Conclusions
There is a strong added value in
considering HTA at EU level:
Pooling of expertise, for instance to face the
challenges specific to personalized medicine
Minimised duplication of efforts
Conclusions (2)
Stakeholders involvement is a key
success factor of cooperation at EU
level
A sustainable cooperation is
needed. Long term solutions are
currently being evaluated.
15